June Sherie Almenoff bought $13k of AVTX
director at Avalo Therapeutics, Inc.. 1,000 shares at an average of $12.75, traded Nov 12, 2024, filed Nov 14, 2024.
Score components
- +15RoleDirector
- 0Trade size$13k at market
- +8Relative to holdingsFirst purchase: no shares before this trade
- 0Price contextNo price history yet
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -31.5%, 3m -42.7%, 6m -71.4%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001578563-24-000441, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 12, 2024 | POpen-market purchase Common Stockindirect: By Meadowlark Management, LLC | +500 | $12.50 | $6,250 | 500 | Nov 14, 2024 |
| Nov 13, 2024 | POpen-market purchase Common Stockindirect: By Meadowlark Management, LLC | +500 | $13.00 | $6,500 | 1,000 | Nov 14, 2024 |
Related signals
Other insiders at Avalo Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 4Weak | Avalo Therapeutics, Inc. | Christopher Ryan Sullivan Chief Financial Officer | $202k 12,394 shares | -24% | |
| 12Weak | Avalo Therapeutics, Inc. | Christopher Ryan Sullivan Chief Financial Officer | $179k 10,185 shares | -20% | |
| 0Weak | Avalo Therapeutics, Inc. | Mittie Doyle Chief Medical Officer | $14k 679 shares | -1% | |
| 0Weak | Avalo Therapeutics, Inc. | Mittie Doyle Chief Medical Officer | $26k 1,450 shares | -3% | |
| 0Weak | Avalo Therapeutics, Inc. | Mittie Doyle Chief Medical Officer | $11k 679 shares | -1% | |
| 12Weak | Avalo Therapeutics, Inc. | Mittie Doyle Chief Medical Officer | $56k 3,000 shares | -45% | |
| 39Weak | Avalo Therapeutics, Inc. | Christopher Ryan Sullivan Chief Financial Officer | $449k 18,606 shares | -98% | |
| 40Moderate | Avalo Therapeutics, Inc. | Paul Varki Chief Legal Officer | $1.5M 75,063 shares | -95% | |
| 38Weak | Avalo Therapeutics, Inc. | Mitchell Chan director | $72k 3,167 shares | -50% | |
| 46Moderate | Avalo Therapeutics, Inc. | Christopher Ryan Sullivan Chief Financial Officer | $949k 47,000 shares | -99% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.